The shares issued to EarlyBirdCapital are part of a previously effective registration statement on Form ... SIL-204 substantially reduced tumor growth in pancreatic cancer models, simulating human ...

The shares issued to EarlyBirdCapital are part of a previously effective registration statement on Form S-1 ... systemic administration of SIL-204 substantially reduced tumor growth in pancreatic ...

The research team at the Atapuerca archaeological sites in Burgos, Spain, has just broken its own record by discovering, for ...

Department of Anatomy researcher Professor Siân Halcrow is collaborating with two biological anthropology colleagues from the ...

MIT engineers have made a breakthrough in this area—they’ve developed a method to grow muscle tissue that contracts in ...

Merger Completion: On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker “SLXN.” This strategic ...

The debut of synthetic biological intelligence marks an unprecedented milestone in the fields of biotechnology and artificial intelligence (AI). Researchers ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

The left hip and leg bones from a young female Paranthropus robustus discovered in South Africa show she was extremely short ...

including Silexion's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking ...

Does manifest destiny enter into advancing AI and attaining artificial general intelligence (AGI) or artificial ...